Being overweight as a child and young adult linked to bowel cancer
Being overweight as a child, teenager and young adult has been linked to a higher risk of bowel cancer in adulthood, researchers suggest.
A higher birth weight was also associated with an increased chance of developing the disease, according to a study.
Experts in the Netherlands reviewed 37 studies on body weight in early life and the risk of colorectal cancer - also known as bowel cancer - in adults.
Cancer is a complex disease which develops over several decades, so better understanding of its early origins is critical for more effective prevention efforts and understanding the research gaps.
The research, which is published in the International Journal of Cancer, found an increase in BMI of 5kg/m² heightened the risk of bowel cancer by 12% in people aged 18 to 25.
In youngsters aged 10 to 19, an increased BMI was linked to a 5-18% risk of developing the disease, while in children aged two to nine, BMI was linked to a higher risk of colon cancer.
Meanwhile, each 1kg increase in birth weight was linked to a 9% bowel cancer risk, the study found.
Dr. Dieuwertje Kok, associate professor of nutrition and cancer at Wageningen University & Research, said: "Although the relationship between adult body size and colorectal cancer risk is well-documented, the potential influence of measures of body size during early life is less understood.
"The team was excited to review results from 37 publications that explored birth weight, as well as body mass index across different early life stages.
"This study bridges the existing knowledge gap and enhances our understanding of how early life factors may affect colorectal cancer risk in adults."
Bowel cancer is the third most common cancer worldwide, according to the WHO, with most cases occurring in people aged 50 and above.
The analysis is part of World Cancer Research Fund International's Global Cancer Update Programme.
Dr. Helen Croker, assistant director of research and policy at the World Cancer Research Fund, added: "Cancer is a complex disease which develops over several decades, so better understanding of its early origins is critical for more effective prevention efforts and understanding the research gaps.
"The results of this study show that raised body mass index across childhood through young adulthood is an important risk factor for colorectal cancer."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
3 hours ago
- Yahoo
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
South Africa Is Rising Up Out of The Ocean, Scientists Reveal
As climate change intensifies, South Africa is not only becoming hotter and drier; it's also rising by up to 2 millimeters per year, according to a new study. Scientists knew this uplift was happening, but the prevailing explanation attributed it to mantle flow within Earth's crust beneath the country. The new study suggests the uplift is caused by recent droughts and the resulting loss of water, a trend linked to global climate change. The discovery emerged due to a network of global navigation satellite system (GNSS) stations in South Africa. Mainly used for atmospheric research, this network provides precise data on the height of various sites across the country. "This data showed an average rise of 6 millimeters between 2012 and 2020," says geodesist Makan Karegar from the University of Bonn. Experts had ascribed this phenomenon to the Quathlamba hotspot. A localized bulge in Earth's crust could form from the upswelling of material from a suspected mantle plume beneath the region, spurring the recent uplift. "However, we have now tested another hypothesis," Karegar says. "We believe it is also possible that a loss of groundwater and surface water is responsible for the land uplift." To explore this possibility, Karegar and his colleagues analyzed the GNSS height data along with precipitation patterns and other hydrological variables across regions of South Africa. A strong association stood out. Areas where severe droughts have occurred in recent years underwent an especially dramatic uplift of land. The rise was most pronounced during the 2015–2019 drought, a period when Cape Town faced the looming threat of "day zero" – a day with no water. The study also looked at data from the GRACE satellite mission, a joint effort by NASA and the German Aerospace Center to measure Earth's gravity field and changes in water distribution. "These results can be used to calculate, among other things, the change in the total mass of the water storage, including the sum of surface water, soil moisture, and groundwater," says University of Bonn geodesist Christian Mielke. "However, these measurements only have a low spatial resolution of several hundred kilometers." Despite this low resolution, GRACE satellite data supported the hypothesis: Places with less water mass had higher uplift at nearby GNSS stations. The team used hydrological models for higher-resolution insight into how droughts can influence the water cycle. "This data also showed that the land uplift could primarily be explained by drought and the associated loss of water mass," Mielke says. The researchers suggest that in addition to upward pressure from a mantle plume, the loss of moisture in the crust could also cause it to bulge. This is another example of the many ways climate change is tweaking the world around us, but it could also offer practical value. GNSS data, which are cost-effective and simple to collect, could offer a new way to track water scarcity, including critical groundwater resources – widely overexploited by humans for agriculture and other purposes. Given the dire threat droughts pose in South Africa, as well as many other parts of the world, this finding may provide a valuable window into water availability. The study was published in the Journal of Geophysical Research: Solid Earth. An Extreme Drop in Oxygen Will Eventually Suffocate Most Life on Earth The Ocean Is Getting Darker, Threatening All That Lives Within Your Salad Could Be Carrying Microplastics From Soil Into Your Body